

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptal617srh

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 11:02:27 ON 23 DEC 2005

```
=> fil reg
COST IN U.S. DOLLARS
SINCE FILE          TOTAL
ENTRY          SESSION
FULL ESTIMATED COST          0.21          0.21
```

FILE 'REGISTRY' ENTERED AT 11:02:37 ON 23 DEC 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 22 DEC 2005 HIGHEST RN 870600-23-0  
 DICTIONARY FILE UPDATES: 22 DEC 2005 HIGHEST RN 870600-23-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.



```
*****
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now      *
* available and contains the CA role and document type information. *
*****
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS  
 for details.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=>
Uploading C:\Program Files\Stnexp\Queries\09890875.str
```



```
chain nodes :
7 8 11 13
ring nodes :
1 2 3 4 5
chain bonds :
1-7 2-8 3-13 4-11
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 1-7 2-3 2-8 3-4 3-13 4-5 4-11
```

G1:O,OH

G2:S,H

G3:H,O

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 11:CLASS 13:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 O,OH

G2 S,H

G3 H,O

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 11:02:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 457474 TO ITERATE

0.4% PROCESSED 2000 ITERATIONS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*INCOMPLETE\*\*

BATCH \*\*INCOMPLETE\*\*



PROJECTED ITERATIONS: 9111153 TO 9187807

PROJECTED ANSWERS: 281018 TO 295398

L2 50 SEA SSS SAM L1

=>

Uploading C:\Program Files\Stnexp\Queries\09890875 sp.str



chain nodes :

```
7 8 11 13
ring nodes :
1 2 3 4 5
chain bonds :
1-7 2-8 3-13 4-11
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-5 1-7 2-8 3-13 4-5 4-11
exact bonds :
1-2 2-3 3-4
isolated ring systems :
containing 1 :
```

G1:O,OH

G2:S,H

G3:H,O

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 11:CLASS 13:CLASS

L3 STRUCTURE UPLOADED

```
=> s 13
SAMPLE SEARCH INITIATED 11:03:48 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 48613 TO ITERATE
```

```
4.1% PROCESSED 2000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```


```
FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 959108 TO 985412
PROJECTED ANSWERS: 58879 TO 65569
```

L4 50 SEA SSS SAM L3

=> d scan

```
L4 50 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1R,2R)-2-
(phenylmethoxy)cyclopentyl]amino]methyl]phenyl] - (9CI)
MF C25 H29 N5 O2
```

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

2.58 2.79

FILE 'STNGUIDE' ENTERED AT 11:06:12 ON 23 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Dec 16, 2005 (20051216/UP).

=> FIL REGISTRY

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

0.06 2.85

FILE 'REGISTRY' ENTERED AT 11:06:17 ON 23 DEC 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 22 DEC 2005 HIGHEST RN 870600-23-0

DICTIONARY FILE UPDATES: 22 DEC 2005 HIGHEST RN 870600-23-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*
\* The CA roles and document type information have been removed from \*
\* the IDE default display format and the ED field has been added, \*
\* effective March 20, 2005. A new display format, IDERL, is now \*
\* available and contains the CA role and document type information. \*
\* \*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

```
=> s 13 full
FULL SEARCH INITIATED 11:06:49 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 972505 TO ITERATE
```

```
100.0% PROCESSED 972505 ITERATIONS 72868 ANSWERS
SEARCH TIME: 00.00.04
```

```
L5 72868 SEA SSS FUL L3
```

```
=> s 1/nr
L6 3420614 1/NR
```

```
=> s 15 and 16
L7 19619 L5 AND L6
```

```
=> fil hcapl
COST IN U.S. DOLLARS SINCE FILE TOTAL
                           ENTRY SESSION
FULL ESTIMATED COST           168.94 171.79
```

```
FILE 'HCAPLUS' ENTERED AT 11:10:58 ON 23 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 23 Dec 2005 VOL 144 ISS 1
FILE LAST UPDATED: 22 Dec 2005 (20051222/ED)
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s 17
L8 33258 L7
```

```
=> s growth factor
    1235054 GROWTH
    4268 GROWTHS
    1237243 GROWTH
        (GROWTH OR GROWTHS)
    936110 FACTOR
```


837816 FACTORS  
1477824 FACTOR  
(FACTOR OR FACTORS)  
L9 174454 GROWTH FACTOR  
(GROWTH (W) FACTOR)

=> s 19 and 18  
L10 421 L9 AND L8

=> s 18 (S) 19  
L11 89 L8 (S) L9

=> d ibib abs 87-89


L11 ANSWER 87 OF 89 HCPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1979:414082 HCPLUS  
DOCUMENT NUMBER: 91:14082  
TITLE: Hormonal regulation of proliferation in two populations of rabbit endometrial cells in culture  
AUTHOR(S): Gerschenson, L. E.; Conner, E. A.; Yang, J.; Andersson, M.  
CORPORATE SOURCE: Med. Cent., Univ. Colorado, Denver, CO, 80262, USA  
SOURCE: Life Sciences (1979), 24(15), 1337-43  
CODEN: LIFSAK; ISSN: 0024-3205  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



AB A technique to culture rabbit primary endometrium epithelial cells in chemical defined medium, whose proliferation was determined to respond to estrogens and progesterone (I) [57-83-0] was previously described. The cultures were made up of 2 cell populations: quiescent and dividing cells. Techniques are described to select for these 2 cell populations using thymidine-3H and cytosine arabinoside or Colcemid. The quiescent cells were the only target for the growth-promoting effect of estrogens. Epidermal growth factor [62229-50-9] and PGF2 $\alpha$  [551-11-1] stimulated the proliferation of both cell populations. I did not antagonize the effect of estrogen on the quiescent cells unless the hormone was incubated previously with a mixed cell culture. The existence of a I putative factor (PPF) resulting from the interaction of I and dividing cells and which is involved in the inhibition of the estrogenic effect on endometrial cell proliferation is suggested. Two other progestins did not have the same effect as I, showing the specificity of I action.


L11 ANSWER 88 OF 89 HCPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1979:115652 HCPLUS  
DOCUMENT NUMBER: 90:115652  
TITLE: Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants  
AUTHOR(S): BenEzra, David  
CORPORATE SOURCE: Natl. Eye Inst., NIH, Bethesda, MD, USA

SOURCE: American Journal of Ophthalmology (1978), 86(4), 455-61  
 CODEN: AJOPAA; ISSN: 0002-9394  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB Prostaglandins E1 (I) [745-65-3], E2 [363-24-6], D2 [41598-07-6], A1 [14152-28-4], F1 $\alpha$  [745-62-0], and F2 $\alpha$  [551-11-1] as well as synthetic chemoattractants and **growth factors** were tested for their ability to induce the proliferation of new blood vessels in rabbit cornea. I showed the strongest neovasculogenic activity attracting new blood vessels in all of the cases. PGE2 was a weaker attractant than I. PGF2 $\alpha$  induced a less consistent reaction. All implants sequestering PGD2 or PGA1 were neg. Implants sequestering 1  $\mu$ g of fibroblast growth factor [62031-54-3] or epidermal growth factor [62229-50-9] variably stimulated the proliferation of keratocytes and epithelial cells in vivo. However, none of these demonstrated any vasculogenic activity. A small, but significant neovascularization was observed only in implants sequestering 10  $\mu$ g of growth factor per implant. Although active in vitro, nerve growth factor and formylated synthetic peptides were not stimulatory in vivo.

L11 ANSWER 89 OF 89 HCPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 1977:496528 HCPLUS  
 DOCUMENT NUMBER: 87:96528  
 TITLE: Epidermal growth factor stimulates prostaglandin biosynthesis by canine kidney (MDCK) cells  
 AUTHOR(S): Levine, Lawrence; Hassid, Aviv  
 CORPORATE SOURCE: Dep. Biochem., Brandeis Univ., Waltham, MA, USA  
 SOURCE: Biochemical and Biophysical Research Communications (1977), 76(4), 1181-7  
 CODEN: BBRCA9; ISSN: 0006-291X  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB Serum and(or) arachidonic acid [506-32-1] stimulated prostaglandin (PGF2 $\alpha$ ) (I) [551-11-1], PGE2 [363-24-6]) production by dog kidney epithelial-like (MDCK) cells. Epidermal growth factor (EGF) [62229-50-9] at concns. of 10 $\cdot$ 9 $\cdot$ 10 $\cdot$ 10M stimulated the biosynthesis of prostaglandins by MDCK cells but not that by human fibroblasts (D-550), mouse fibroblasts (3T3),

transformed mouse fibroblasts (MC5-5), and rabbit aorta endothelial cells (CLO). EGF also stimulated the release of radioactivity from MDCK cells radioactively labeled with arachidonic acid-3H.

=> fil reg			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	22.65	194.44	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL	
	ENTRY	SESSION	
CA SUBSCRIBER PRICE	-2.19	-2.19	

FILE 'REGISTRY' ENTERED AT 11:14:29 ON 23 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 DEC 2005 HIGHEST RN 870600-23-0  
DICTIONARY FILE UPDATES: 22 DEC 2005 HIGHEST RN 870600-23-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.



\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\09890875 sp b.str



```

chain nodes :
6 7 8 9 10 11 12 15 16
ring nodes :
1 2 3 4 5
chain bonds :
1-6 2-7 3-8 7-9 8-10 9-12 9-15 10-11 10-16
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-6 2-7 3-8 7-9 8-10 9-12 9-15 10-11 10-16
exact bonds :
1-2 1-5 2-3 3-4 4-5
isolated ring systems :
containing 1 :

```

G1:H,Cy,Ak

Match level :


```

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 15:CLASS 16:CLASS

```

L12 STRUCTURE UPLOADED

=> d  
L12 HAS NO ANSWERS  
L12 STR



G1 H,Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> d his

```

(FILE 'HOME' ENTERED AT 11:02:27 ON 23 DEC 2005)

FILE 'REGISTRY' ENTERED AT 11:02:37 ON 23 DEC 2005
L1      STRUCTURE UPLOADED
L2      50 S L1
L3      STRUCTURE UPLOADED
L4      50 S L3

FILE 'STNGUIDE' ENTERED AT 11:06:12 ON 23 DEC 2005

FILE 'REGISTRY' ENTERED AT 11:06:17 ON 23 DEC 2005
L5      72868 S L3 FULL
L6      3420614 S 1/NR
L7      19619 S L5 AND L6

```

FILE 'HCAPLUS' ENTERED AT 11:10:58 ON 23 DEC 2005  
L8 33258 S L7  
L9 174454 S GROWTH FACTOR  
L10 421 S L9 AND L8  
L11 89 S L8 (S) L9

FILE 'REGISTRY' ENTERED AT 11:14:29 ON 23 DEC 2005  
L12 STRUCTURE uploaded

=> s l12 sub=15 full  
FULL SUBSET SEARCH INITIATED 11:15:04 FILE 'REGISTRY'  
FULL SUBSET SCREEN SEARCH COMPLETED - 1231 TO ITERATE

100.0% PROCESSED 1231 ITERATIONS 0 ANSWERS  
SEARCH TIME: 00.00.01

L13 0 SEA SUB=L5 SSS FUL L12

=> s l12  
SAMPLE SEARCH INITIATED 11:15:16 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 7386 TO ITERATE

27.1% PROCESSED 2000 ITERATIONS 1 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 142568 TO 152872  
PROJECTED ANSWERS: 1 TO 188

L14 1 SEA SSS SAM L12

=> d

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 149816-52-4 REGISTRY  
ED Entered STN: 04 Sep 1993  
CN Butanoic acid, 5-oxo-3-(1-propenyl)-3-cyclopentene-1,2-diyl ester,  
[1 $\alpha$ ,2 $\beta$ ,3(E)]- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Butanoic acid, 5-oxo-3-(1-propenyl)-3-cyclopentene-1,2-diyl ester,  
[1 $\alpha$ ,2 $\beta$ ,3(E)]- (±)-  
FS STEREOSEARCH  
MF C16 H22 O5  
SR CA  
LC STN Files: CA, CAPLUS

Relative stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 112 full  
FULL SEARCH INITIATED 11:15:37 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 148788 TO ITERATE


100.0% PROCESSED 148788 ITERATIONS 69 ANSWERS  
SEARCH TIME: 00.00.04

L15 69 SEA SSS FUL L12

=> d scan

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(acetyloxy)methyl]-, cis- (9CI)  
MF C12 H14 O7

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):68

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-(methoxymethyl)-, (4R-trans)- (9CI)  
MF C11 H14 O6

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Butanoic acid, 5-oxo-3-(1-propenyl)-3-cyclopentene-1,2-diyil ester,


[1 $\alpha$ ,2 $\beta$ ,3(E)]- (9CI)  
MF C16 H22 O5

Relative stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Decanoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
MF C25 H42 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Benzoic acid, 4-(dimethylamino)-, (1R,2S)-5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
MF C23 H24 N2 O5


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(acetyloxy)methyl]-, (4R,5S)-  
 (9CI)  
 MF C12 H14 O7


Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(benzoyloxy)-3-(1-propenyl)-,  
 [4S-[3(E),4α,5β]]- (9CI)  
 MF C22 H18 O5


Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-(methoxymethyl)-, cis- (9CI)  
MF C11 H14 O6


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-methyl-2-[(2,3,4,6-tetra-O-acetyl- $\alpha$ -D-glucopyranosyl)oxy]- (9CI)  
MF C24 H30 O15

Absolute stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-3-(1E)-1-propenyl-, (4R,5S)-rel- (9CI)  
MF C12 H14 O5


Relative stereochemistry.

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(1-oxoproxy)- (9CI)  
 MF C11 H14 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN Octadecanoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
 MF C41 H74 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[1-(acetyloxy)tridecyl]-, (4R,5S)-rel- (9CI)  
 MF C24 H38 O7

Relative stereochemistry.  
 Currently available stereo shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(benzoyloxy)-3-(1,2-dihydroxypropyl)- (9CI)  
 MF C22 H20 O7



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Propenoic acid, 3-[4,5-bis(acetoxy)-3-oxo-1-cyclopenten-1-yl]-, methyl ester, [1(E),4α,5β]- (9CI)  
 MF C13 H14 O7

Relative stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetoxy)- (9CI)  
 MF C9 H10 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(benzoyloxy)-3-(1-propenyl)-,  
 [3(E),4α,5β]- (9CI)  
 MF C22 H18 O5

Relative stereochemistry.  
 Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN Octanoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
 MF C21 H34 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 3-Octadecenoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
 MF C41 H70 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(1-acetyloxy)pentadecyl]-,  
 (4R,5R)-rel- (9CI)  
 MF C26 H42 O7

Relative stereochemistry.  
 Currently available stereo shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(benzoyloxy)-3-[(2,2,5-trimethyl-1,3-dioxolan-4-yl)-]-, (9CI)  
 MF C25 H24 O7



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(1-methoxymethyl)-], trans-, (9CI)  
 MF C11 H14 O6


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(acetyloxy)methyl]-,  
 (4S-trans)- (9CI)  
 MF C12 H14 O7


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-, trans- (9CI)  
 MF C9 H10 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN Pentanoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
 MF C15 H22 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Hexenoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
 MF C17 H22 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 3,4,5-trihydroxy-, triacetate (5CI)  
 MF C11 H12 O7



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Propenal, 3-[4,5-bis(acetyloxy)-3-oxo-1-cyclopenten-1-yl]-,  
 [4R-[1(E),4α,5β]]- (9CI)  
 MF C12 H12 O6


Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-(ethoxymethyl)-, trans- (9CI)  
 MF C12 H16 O6


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(acetyloxy)methyl]-2-bromo-,  
 (4S-trans)- (9CI)  
 MF C12 H13 Br O7


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN Acetamide, N-[3,4-bis(acetyloxy)-5-oxo-1-cyclopenten-1-yl]-, (3R-cis)-  
 (9CI)  
 MF C11 H13 N O6


Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Hexenoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester, (2E,2'E)- (9CI)  
 MF C17 H22 O5

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN Propanoic acid, 2-methyl-, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
 MF C13 H18 O5




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(acetyloxy)methyl]-2-bromo- (9CI)  
 MF C12 H13 Br O7



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-3-(3-hydroxy-1-octenyl)- (9CI)  
 MF C17 H24 O6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(1-methylethoxy)methyl]-, trans- (9CI)  
 MF C13 H18 O6

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-methyl-2-[(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)oxy]-, (4S-cis)- (9CI)  
 MF C24 H30 O15



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN Butanoic acid, 5-oxo-3-cyclopentene-1,2-diyil ester (9CI)  
 MF C13 H18 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-, (4R,5S)- (9CI)  
 MF C9 H10 O5


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Butenedioic acid (2E)-, 5-oxo-3-cyclopentene-1,2-diyil dimethyl ester  
 (9CI)  
 MF C15 H14 O9


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(acetyloxy)methyl]-2-bromo-,  
 (4S-cis)- (9CI)  
 MF C12 H13 Br O7


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-3-methyl-, cis- (9CI)  
 MF C10 H12 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(phenylthio)methyl]-, trans-


(9CI)  
MF C16 H16 O5 S

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-methyl-2-[(2,3,4,6-tetra-O-acetyl- $\beta$ -D-galactopyranosyl)oxy]-, (4S-trans)- (9CI)  
MF C24 H30 O15



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 3-Octenoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
MF C21 H30 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Cyclopenten-1-one, 4,5-bis(benzoyloxy)-, (4R,5S)- (9CI)  
MF C19 H14 O5


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Butenedioic acid (2Z)-, 5-oxo-3-cyclopentene-1,2-diyl dimethyl ester  
 (9CI)  
 MF C15 H14 O9


Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(acetyloxy)methyl]-, (4S,5S)-  
 (9CI)  
 MF C12 H14 O7

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-3-[(3-[(tetrahydro-2H-pyran-2-yl)oxy]-1-octenyl)- (9CI)  
 MF C22 H32 O7



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(phenylmethyl)thiomethyl]-, trans- (9CI)  
 MF C17 H18 O5 S

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-3-(2-methoxypropyl)- (9CI)  
 MF C13 H18 O6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(benzoyloxy)- (9CI)  
 MF C19 H14 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-, (4S,5R)- (9CI)  
 MF C9 H10 O5

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN Acetic acid, methoxy-, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
 MF C11 H14 O7



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopentene-1-carboxylic acid, 1,5-bis(acetyloxy)-3-chloro-4-oxo-2-(1-propenyl)-, methyl ester, [1R-[1α,2(E),5β]]- (9CI)  
 MF C14 H15 Cl O7


Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN Acetic acid, trifluoro-, 2-(acetyloxy)-5-oxo-3-(1-propenyl)-3-cyclopenten-1-yl ester, [1R-[1 $\alpha$ ,2 $\beta$ ,3(E)]]- (9CI)  
 MF C12 H11 F3 O5


Absolute stereochemistry.  
 Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-4-methyl-, trans- (9CI)  
 MF C10 H12 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2H-Pyran-2-one, 4-(acetyloxy)-6-[2-[4,5-bis(acetyloxy)-3-oxo-1-cyclopenten-1-yl]ethenyl]tetrahydro-, [4 $\alpha$ ,6 $\beta$ [E(4S\*,5R\*)]]- (9CI)  
 MF C18 H20 O9


Relative stereochemistry.

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Hexanoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
MF C17 H26 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Cyclopenten-1-one, 4,5-bis(benzoyloxy)-, (4S,5R)- (9CI)  
MF C19 H14 O5

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Propanedioic acid, methyl-, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
MF C13 H14 O9



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN Butanoic acid, 5-oxo-1-[(1-oxobutoxy)methyl]-3-cyclopentene-1,2-diyI ester, (1S-cis)- (9CI)  
 MF C18 H26 O7


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-5-[(acetyloxy)methyl]-, trans- (9CI)  
 MF C12 H14 O7


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-4-methyl-, cis- (9CI)  
 MF C10 H12 O5


Relative stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-3-(1-decenyl)-,  
[3(E),4 $\alpha$ ,5 $\beta$ ] - (9CI)  
MF C19 H28 O5

Relative stereochemistry.  
Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Tetradecanoic acid, 5-oxo-3-cyclopentene-1,2-diyl ester (9CI)  
MF C33 H58 O5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Benzoic acid, 4-(dimethylamino)-, (1S,2R)-5-oxo-3-cyclopentene-1,2-diyl  
ester (9CI)  
MF C23 H24 N2 O5


Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-3-propyl-, (4R,5S)-rel- (9CI)  
 MF C12 H16 O5

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L15 69 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
 IN 2-Cyclopenten-1-one, 4,5-bis(acetyloxy)-3-(1-propenyl)-, trans- (9CI)  
 MF C12 H14 O5

Relative stereochemistry.

Double bond geometry unknown.

Currently available stereo shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> fil hcapl			
COST IN U.S. DOLLARS	SINCE FILE	TOTAL	
	ENTRY	SESSION	
FULL ESTIMATED COST	202.08	396.52	
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL	
	ENTRY	SESSION	
CA SUBSCRIBER PRICE	0.00	-2.19	

FILE 'HCAPLUS' ENTERED AT 11:16:12 ON 23 DEC 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Dec 2005 VOL 144 ISS 1  
FILE LAST UPDATED: 22 Dec 2005 (20051222/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 115  
L16 44 L15

=> s 116 and (treat? or therap?)  
3290486 TREAT?  
445371 THERAP?  
L17 14 L16 AND (TREAT? OR THERAP?)

=> d ibib abs 12-14


L17 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1985:113124 HCAPLUS  
DOCUMENT NUMBER: 102:113124  
TITLE: Studies related to cyclopentanoid natural products.  
Part 3. Synthesis of pentenomycin and its racemate  
Hetzmanski, Michael; Purcell, Neil; Stoodley, Richard  
J.; Palfreyman, Malcolm N.  
AUTHOR(S):  
CORPORATE SOURCE: Dep. Org. Chem., Univ. Newcastle upon Tyne, Newcastle  
upon Tyne, NE1 7RU, UK  
SOURCE: Journal of the Chemical Society, Perkin Transactions  
1: Organic and Bio-Organic Chemistry (1972-1999)  
(1984), (9), 2089-96  
CODEN: JCPRB4; ISSN: 0300-922X  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI



AB The 4R cyclopentenone I ( $R = \text{CH}_2\text{Ph}$ ) reacted with  $\text{OsO}_4$  to give diol II, the cis hydroxylation having occurred anti to the 4-benzyloxy group. A subsequent hydrogenolysis-dehydration sequence converted II into pentenomycin (III;  $R = R_1 = R_2 = \text{H}$ ). Although the optical rotations of synthetic III ( $R = R_1 = R_2 = \text{H}$ ) and its derivs. III (R = H, Br, R<sub>1</sub> = R<sub>2</sub> = Ac; R = R<sub>2</sub> = H, R<sub>1</sub> = CH<sub>2</sub>Ph) were substantially different from literature values, the compds. are enantiomerically pure. Treatment of the dithiaspiro[3.2]hexane IV ( $R = \text{H}$ ,  $R_1 = \text{CH}_2\text{OH}$ ) with  $\text{Me}_3\text{CSiMe}_2\text{Cl}$  gave IV ( $R = \text{SiMe}_2\text{CMe}_3$ ,  $R_1 = \text{CH}_2\text{OSiMe}_2\text{CMe}_3$ ) which reacted with  $(\text{PhSeO})_2\text{O}$  to give I ( $R = \text{SiMe}_2\text{CMe}_3$ ), subsequent reactions of which with  $\text{OsO}_4$  and  $\text{HCl}$  gave pentenomycin. Racemic I ( $R = \text{SiMe}_2\text{CMe}_3$ ), prepared from racemic I ( $R = \text{H}$ ) and  $\text{Me}_3\text{CSiMe}_2\text{Cl}$ , was transformed analogously into racemic pentenomycin.

L17 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1983:453439 HCAPLUS  
 DOCUMENT NUMBER: 99:53439  
 TITLE: Syntheses of ( $\pm$ )- and (-)-O-pentenomycin I  
 AUTHOR(S): Elliott, John D.; Hetmanski, Michael; Palfreyman, Malcolm N.; Purcell, Neil; Stoodley, Richard J.  
 CORPORATE SOURCE: Dep. Org. Chem., Univ. Newcastle upon Tyne, Newcastle upon Tyne, NE1 7RU, UK  
 SOURCE: Tetrahedron Letters (1983), 24(9), 965-8  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 99:53439  
 GI




AB ( $\pm$ )-Pentenomycin I [ $(\pm)$ -I] and (-)-pentenomycin I [(-)-I] were prep'd in several steps from 3-(hydroxymethyl)-2-methylfuran and from D-(-)-quinic acid, resp. A key step in the latter synthesis was the

conversion of the diol II into the cyclopentenecarboxaldehyde III in 72% yield by sequential **treatment** with  $\text{Pb}(\text{OAc})_4$  in  $\text{CH}_2\text{Cl}_2$  and pyrrolidinium acetate in  $\text{C}_6\text{H}_6$ .

L17 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1979:71825 HCAPLUS  
DOCUMENT NUMBER: 90:71825  
TITLE: Prostaglandin intermediates from a mold metabolite  
INVENTOR(S): Mitscher, Lester Allen; Clark, George Winfred, III;  
Bokelman, Gordon Herman  
PATENT ASSIGNEE(S): Ohio State University Research Foundation, USA  
SOURCE: U.S., 9 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4103091	A	19780725	US 1976-707726	19760722
US 4188329	A	19800212	US 1978-904831	19780511
PRIORITY APPLN. INFO.:			US 1975-611468	A2 19750908
			US 1976-707726	A3 19760722

GI



AB The prostaglandin intermediate I was prepared from terrein (II) by 2 similar routes involving benzoylation or acetylation, resp. Thus, terrein dibenzoate was hydroxylated with  $\text{OsO}_4$ , reduced with  $\text{Zn}(\text{BH}_4)_2$ , oxidized to the aldehyde with  $\text{NaIO}_4$ , **treated** with  $\text{C}_5\text{H}_11\text{COCH}_2\text{P}(\text{O})(\text{OMe})_2$ , acylated with  $\text{EtO}_2\text{CCH}_2\text{COCl}$ , cyclized with  $\text{Me}_3\text{CONa}$  to III, decarboxylated, and reduced with  $\text{Zn}$  dust to give I.


=> d ibib abs 1-11

L17 ANSWER 1 OF 14 HCPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2005:962192 HCPLUS  
DOCUMENT NUMBER: 143:244920  
TITLE: Extraction of hygrophorone derivatives for

INVENTOR(S) : pharmaceutical use as antibacterial and fungicidal agents  
 Wessjohann, Ludger A.; Arnold, Norbert; Luebken, Tilo;  
 Locher, Hans  
 PATENT ASSIGNEE(S) : Leibniz-Institut fuer Pflanzenbiochemie IPB, Germany  
 SOURCE: PCT Int. Appl., 45 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005080311	A1	20050901	WO 2005-EP1957	20050224
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004009185	A1	20050915	DE 2004-102004009185	20040225
PRIORITY APPLN. INFO.:			DE 2004-102004009185A	20040225
			DE 2004-102004015566A	20040330


OTHER SOURCE(S) : MARPAT 143:244920  
 GI



AB This invention relates to the extraction of hygrophorone derivs., such as 4,6-di-O-acetylhygrophorone A12 (I), from various Hygrophorus species for **therapeutic** use as fungicidal or antibacterial agents.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 14 HCPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:341263 HCPLUS  
 DOCUMENT NUMBER: 141:67971  
 TITLE: Hygrophorones A-G: fungicidal cyclopentenones from  
 Hygrophorus species (Basidiomycetes)  
 AUTHOR(S): Lubken, Tilo; Schmidt, Jurgen; Porzel, Andrea; Arnold,  
 Norbert; Wessjohann, Ludger  
 CORPORATE SOURCE: Department of Bioorganic Chemistry, Leibniz-Institute  
 of Plant Biochemistry, Halle/Saale, D-06120, Germany  
 SOURCE: Phytochemistry (Elsevier) (2004), 65(8), 1061-1071  
 PUBLISHER: Elsevier Science B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB Twenty new 5-(hydroxyalkyl)-2-cyclopentenone derivs. (hygrophorones, e.g. I) could be isolated from *Hygrophorus latitabundus*, *H. olivaceoalbus*, *H. persoonii*, and *H. pustulatus*. Their fungicidal activity was exemplarily tested. The hygrophorones have structural similarities to the antibiotic pentenomycin. Chemical, hygrophorones are 2-cyclopentenones with hydroxy or acetoxy substituents at C-4 and/or C-5. An odd-numbered 1' oxidized alkyl chain (C11, C13, C15, or C17) is attached at C-5. In addition, from *H. persoonii* the new  $\gamma$ -butyrolactone derivative 5-(E)-2-hydroxytetradexylidene-5H-furan-2-one could be isolated. Some hygrophorones are responsible for the color reaction of the stipes of these fungi upon **treatment** with potassium hydroxide solution. Structural elucidations are based on 1D (1H, 13C) and 2D (COSY, NOESY, HSQC, HMBC) NMR spectroscopic analyses as well as HR-FT-ICR-MS investigations.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:592544 HCAPLUS

DOCUMENT NUMBER: 133:176974

TITLE: Preparation of 4,5-dihydroxy-2-cyclopenten-1-one, 4-hydroxy-2-cyclopenten-1-one, and derivatives thereof as promoters for production of interleukin-12 and growth factor

INVENTOR(S): Ohnogi, Hiromu; Akiyama, Kaori; Tominaga, Takanari; Nishiyama, Eiji; Wu, Hua-kang; Tatsumi, Yoko; Sagawa, Hiroaki; Kato, Ikuonoshin

PATENT ASSIGNEE(S): Takara Shuzo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 50 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000048586	A1	20000824	WO 2000-JP787	20000214
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1170007	A1	20020109	EP 2000-902942	20000214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			JP 1999-42236	A 19990219
			JP 1999-108499	A 19990415
			JP 1999-264539	A 19990917

AB Described are remedies or preventives for diseases with a need for the reinforcement of the production of growth factor and/or diseases with a need for the reinforcement of the production of interleukin-12, characterized by containing as the active ingredient a compound selected from among 4,5-dihydroxy-2-cyclopenten-1-one (I), 4-hydroxy-2-cyclopenten-1-one, and derivs. thereof. These compds. are useful for the **treatment** or prevention of hepatitis, Alzheimer's disease, cancer, diabetes, etc., or as functional food or beverages for maintaining homeostasis. Thus, 10 g D-glucuronic acid was dissolved in 1 L H<sub>2</sub>O and heated at 121° for 4 h, followed by chromatog. purification using a silica gel column BW-300SP (Fuji Silijsia Chemical Ltd., Japan) to give 100 mg I which was esterified by propanoic anhydride in CH<sub>2</sub>Cl<sub>2</sub> in the presence of 4-dimethylaminopyridine and Et<sub>3</sub>N under ice-cooling for 1 h to give 4,5-bis(propanoyloxy)-2-cyclopenten-1-one (II). II in vitro increased the production of nerve growth factor from 0.570 ng/mL (control) to 2.150 ng/mL at 17.5 ng/mL in rat fibroblast cells. An injection solution containing I and a tablet containing II were prepared

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:144898 HCAPLUS

DOCUMENT NUMBER: 132:194660

TITLE: Preparation of cyclopentanone derivatives as apoptosis inducers

INVENTOR(S): Kobayashi, Eiji; Ohnogi, Hiromu; Koyama, Nobuto; Ikai, Katsushige; Sagawa, Hiroaki; Kato, Ikunoshin

PATENT ASSIGNEE(S): Takara Shuzo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000011021	A1	20000302	WO 1999-JP4324	19990810
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9951958	A1	20000314	AU 1999-51958	19990810
EP 1106624	A1	20010613	EP 1999-937011	19990810
EP 1106624	B1	20030409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 236927	E	20030415	AT 1999-937011	19990810
ES 2191446	T3	20030901	ES 1999-937011	19990810
US 6380262	B1	20020430	US 2001-762265	20010206
PRIORITY APPLN. INFO.:			JP 1998-232746	A 19980819
			WO 1999-JP4324	W 19990810

OTHER SOURCE(S): MARPAT 132:194660

GI



AB 5-Membered ring compds. represented by general formula [I; the dotted line in the 5-membered ring represents that this 5-membered ring may be a cyclopentene ring possessing a double bond or a saturated cyclopentane ring; when it is a cyclopentene ring, X = OR1, Y = O, and Z = H; when it is a cyclopentane ring, X = O, Y = OR2, and Z = OR3; R1 = R4, COR5; R2 = H, R6, COR7; R3 = H, R8, COR9; R4 - R9 = aliphatic, aromatic, or araliph. group; provided that a case where R2 = R3 = H is excluded; W = residue derived by removing SH group from a HS-containing compound], optically active isomers thereof, or salts of the same are prepared as well as pharmaceutical formulations containing I. These compds. have physiol. activities including a carcinostatic effect, antiviral activity against influenza virus, and topoisomerase-inhibitory activity. Thus, 10 g D-glucuronic acid was dissolved in 1 L H<sub>2</sub>O, heated at 121° for 4 h, concentrated under reduced pressure, mixed with a 3:2:2 mixture of tert-Bu acetate, AcOH, and H<sub>2</sub>O (40 mL), and centrifuged. The supernatant liquid was concentrated to apprx. 10 mL

and

applied to a silica gel chromatog. column which was eluted with a 3:2:2 mixture of tert-Bu acetate, AcOH, and H<sub>2</sub>O to give 100 mg 4,5-dihydroxy-2-cyclopenten-1-one. The latter compound (44 mg) and tert-Bu 2,2,2-trichloroacetimidate (287 mg) were dissolved in 2.5 mL CH<sub>2</sub>Cl<sub>2</sub> and **treated** dropwise with 1 mL BF<sub>3</sub>.Et<sub>2</sub>O, and stirred at room temperature for 8 h to give, after purification by TLC, 4,5-di(tert-butoxy)-2-cyclopenten-1-one (II) 11, 4-tert-butoxy-5-hydroxy-2-cyclopenten-1-one 9.2, and 5-tert-butoxy-4-hydroxy-2-cyclopenten-1-one 1.9%. II (185 mg) was dissolved in 3.6 mL ethanol, followed by adding 3.6 mL PBS and 252 mg glutathione (reduced form) and adjusting the pH of the solution at 7.5 by adding 1 M Tris-HCl, and the resulting mixture was stirred at room temperature

for

1 h, and concentrated to dryness to give, after purification by TLC, the adduct,

namely 2,3-di(tert-butoxy)-4-(glutathion-S-yl)-1-cyclopentanone (III). III *in vitro* at 34  $\mu$ M induced apoptosis in HL-60 cell and inhibited the proliferation of HL-60.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:34881 HCAPLUS


DOCUMENT NUMBER: 130:95322

TITLE: Preparation of 4,5-dihydroxy-2-cyclopenten-1-one

derivatives as anticancer and apoptosis-inducing  
 agents  
 INVENTOR(S): Kobayashi, Eiji; Koyama, Nobuto; Kato, Ikunoshin;  
 Inami, Kaoru; Shiba, Tetsuo  
 PATENT ASSIGNEE(S): Takara Shuzo Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 38 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9900349	A1	19990107	WO 1998-JP2516	19980605
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2287282	AA	19990107	CA 1998-2287282	19980605
AU 9875516	A1	19990119	AU 1998-75516	19980605
AU 739505	B2	20011011		
EP 1000923	A1	20000517	EP 1998-923158	19980605
EP 1000923	B1	20031203		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1129569	B	20031203	CN 1998-806456	19980605
AT 255554	E	20031215	AT 1998-923158	19980605
ES 2209139	T3	20040616	ES 1998-923158	19980605
JP 3639601	B2	20050420	JP 1999-505418	19980605
TW 555744	B	20031001	TW 1998-87110072	19980623
US 6111145	A	20000829	US 1999-419221	19991015
PRIORITY APPLN. INFO.:			JP 1997-187205	A 19970630
			WO 1998-JP2516	W 19980605

OTHER SOURCE(S): MARPAT 130:95322  
GI



AB Cyclopentenone derivs. of general formula (I) or optically active isomers thereof, or salts of both (wherein R1 and R2 are the same or different and each represents a linear or branched alkyl group, a linear or branched alkenyl group, an aromatic group, an araliph. group or H, excluding the cases in which both R1 and R2 are H, or R1 is benzyl and R2 is H), which are useful for the **treatment** of cancer, viral diseases, rheumatism, diabetes, allergy, autoimmune diseases, and inflammation, are prepared. Thus, 10 g D-glucuronic acid was dissolved in 1 L H<sub>2</sub>O, heated at 121° for 4 h, concentrated to 10 mL volume, stirred with a 3:2:2 mixture of tert-Bu acetate/AcOH/H<sub>2</sub>O, and centrifuged. The supernatant extract was concentrated to 10 mL volume and applied to a BW-300SP silica gel chromatog. column which was eluted with 3:2:2 mixture of tert-Bu acetate/AcOH/H<sub>2</sub>O to give 100 mg 4,5-dihydroxy-2-cyclopenten-1-one, I (R1 = R2 = H) (II). II

was resolved to (−)-(4R,5S)-II and (+)-(4S,5R)-II enantiomer by HPLC using a ChiralPak AS column. II (44 mg) and 492 mg benzyl 2,2,2-trichloroacetimidate were dissolved in 2.5 mL CH<sub>2</sub>Cl<sub>2</sub>, followed by slowly adding 1 mL Et<sub>2</sub>O·BF<sub>3</sub> with stirring, and the stirring was continued at room temperature for 8 h to give I (R<sub>1</sub> = H, R<sub>2</sub> = CH<sub>2</sub>Ph) 3.7, I (R<sub>1</sub> = CH<sub>2</sub>Ph, R<sub>2</sub> = H) 3.7, and I (R<sub>1</sub> = R<sub>2</sub> = CH<sub>2</sub>Ph) 2.5%. I (R<sub>1</sub> = H, R<sub>2</sub> = CH<sub>2</sub>Ph) at 2.44 µg/mL, I (R<sub>1</sub> = CH<sub>2</sub>Ph, R<sub>2</sub> = H) at 19.5 µg/mL, and I (R<sub>1</sub> = R<sub>2</sub> = CH<sub>2</sub>Ph) at 156 µg/mL completely inhibited the proliferation of leukemia HL-60 cells. I (R<sub>1</sub> = R<sub>2</sub> = CH<sub>2</sub>Ph) at ≥250 µM also inhibited topoisomerase II. I (R<sub>1</sub> = H, R<sub>2</sub> = tert-butyl) and I (R<sub>1</sub> = R<sub>2</sub> = tert-butyl) at 1 mg and 10 mg/10 mL olive oil/kg p.o. inhibited carageenan-induced sole edema in rats. Pharmaceutical formulations were prepared

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:693406 HCAPLUS

DOCUMENT NUMBER: 129:275660

TITLE: Preparation of 4,5-diacetoxy-2-cyclopentenone from 2,5-diacetoxy-2,4-pentadienal

INVENTOR(S): Tajima, Kiyohiko

PATENT ASSIGNEE(S): Noguchi Research Institute, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10287616	A2	19981027	JP 1997-114374	19970416
PRIORITY APPLN. INFO.:			JP 1997-114374	19970416
OTHER SOURCE(S):	CASREACT 129:275660			

AB 4,5-Diacetoxy-2-cyclopentenone (I), useful as an antibiotic agent, anticancer agent (no data), and as an intermediate for perfumes and pharmaceuticals, is prepared by treatment of 2,5-diacetoxy-2,4-pentadienal (II) in Ac<sub>2</sub>O in the presence of acids. II was treated with CF<sub>3</sub>CO<sub>2</sub>H at room temperature for 2 h in Ac<sub>2</sub>O to give 73.2% I.

L17 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:603239 HCAPLUS

DOCUMENT NUMBER: 119:203239

TITLE: Preparation of terrein derivatives as anticholesteremics

INVENTOR(S): Kirsch, Reinhard; Hammann, Peter; Granzer, Ernold; Reuschling, Dieter Bernd

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Ger. Offen., 53 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent



LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4142075	A1	19930624	DE 1991-4142075	19911219
PRIORITY APPLN. INFO.:			DE 1991-4142075	19911219
OTHER SOURCE(S):	MARPAT 119:203239			

GI



AB Title compds. [I; R, R6-R8 = H; R1, R2 = H, alkyl, CH2OMe, SiMe3, alkanoyl, alkoxy carbonyl, etc.; R1 = (cyclo)alkyl, (hetero)aryl, OH, alkoxy, CH(OH)CH2CH(OH)CH2CO2Me, sugar residue, etc.; R4 = OH, alkanoyloxy, alkoxy, etc.; or RR4 = O; R5 = H, alkylthio, alkoxy carbonylmethylthio, arylthio, NH2, etc.; or R5R6, R7R8 = bond] were prepared. Thus, bis(silyloxy)cyclopropanone II [R1 = R2 = SiMe2CMe3, R9 = CH2P(O)(OMe)2] was condensed with cyclohexanecarboxaldehyde to give, after deprotection, II (R1 = R2 = H, R9 = 2-cyclohexylvinyl), which after 21 days reduced total serum cholesterol and serum triglycerides from 113 to 92 and 226 to 127% of a normal level, resp., at 10 mg/kg/day orally in cholesterol-fed rabbits.

L17 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:147791 HCAPLUS

DOCUMENT NUMBER: 116:147791

TITLE: Fungal bioconversions yielding unusual antibiotics from carbohydrates. XVI. Enzymic production of echinosporin, a new enantiomerically pure pentenomycin, from 1,4- $\alpha$ -D-glucans

AUTHOR(S): Baute, Marie Antoinette; Deffieux, Gerard; Baute, Robert; Badoc, Alain; Vercauteren, Joseph; Leger, Jean Michel; Neveu, Arlette

CORPORATE SOURCE: Lab. Mycol. Biol. Veg., Fac. Sci. Pharm., Bordeaux, 33000, Fr.

SOURCE: Bulletin de la Societe de Pharmacie de Bordeaux (1990), 129(1-2-3-4), 17-30

CODEN: BSPBAD; ISSN: 0037-9093

DOCUMENT TYPE: Journal

LANGUAGE: French

AB When subjected to activating plasmolytic treatments, the discomycete Peziza echinospora exhibits an enzymic activity which degrades 1,4- $\alpha$ -D-glucans to 1,5-D-anhydrofructose, then converts this sugar to echinosporin. Biogenetic, myocol., and practical consequences of this bioconversion are discussed.

L17 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:510706 HCAPLUS

DOCUMENT NUMBER: 115:110706

TITLE: Fungal enzymic activity degrading 1,4- $\alpha$ -D-glucans to echinosporin (5-epipentenomycin I)

AUTHOR(S): Baute, Marie Antoinette; Deffieux, Gerard; Baute, Robert; Badoc, Alain; Vercauteren, Joseph; Leger, Jean Michel; Neveu, Arlette

CORPORATE SOURCE: Fac. Pharm., Univ. Bordeaux II, Bordeaux, 33000, Fr.

SOURCE: Phytochemistry (1991), 30(5), 1419-23


CODEN: PYTCAS; ISSN: 0031-9422

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 115:110706

GI



AB When subjected to activating plasmolytic **treatments**, the Discomycete *Peziza echinospora* exhibits an enzymic activity which degrades 1,4- $\alpha$ -D-glucans to 1,5-D-anhydrofructose, and then converts this sugar to echinosporin (5-epipentenomycin I, I) that had not been previously reported as a pure enantiomer. Biogenetic, mycol. and practical consequences of this bioconversion are discussed.

L17 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 1991:448910 HCAPLUS  
 DOCUMENT NUMBER: 115:48910  
 TITLE: Preparation of 4,5-diacetoxy-2-cyclopentenone from D-glucofuranurono-6,3-lactone triacetate  
 INVENTOR(S): Tajima, Kiyohiko  
 PATENT ASSIGNEE(S): Noguchi Research Institute, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 02247151	A2	19901002	JP 1989-65286	19890317
JP 07068163	B4	19950726		


PRIORITY APPLN. INFO.: JP 1989-65286 19890317  
 AB 4,5-Diacetoxy-2-cyclopentenone (I), useful as an intermediate for perfumes and pharmaceuticals, is prepared by **treatment** of D-glucofuranurono-6,3-lactone triacetate (II) with pyridine in Ac<sub>2</sub>O, followed by **treatment** with acid catalysts in Ac<sub>2</sub>O. II was **treated** with pyridine in Ac<sub>2</sub>O at 100° for 10 h, concentrated in vacuo, extracted with diisopropyl ether, concentrated, and **treated** with CF<sub>3</sub>CO<sub>2</sub>H in Ac<sub>2</sub>O at room temperature for 4 h to give 33.0% I.

L17 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 1988:75063 HCAPLUS  
 DOCUMENT NUMBER: 108:75063  
 TITLE: Sulfone-mediated synthesis of cyclopentadienone epoxides from 10-oxatricyclo[5.2.1.0<sub>2,6</sub>]decadienones. A convenient route to epi-pentenomycins  
 AUTHOR(S): Klunder, A. J. H.; Houwen-Claassen, A. A. M.; Kooy, M. G.; Zwanenburg, B.  
 CORPORATE SOURCE: Dep. Org. Chem., Univ. Nijmegen, Nijmegen, 6525 ED, Neth.  
 SOURCE: Tetrahedron Letters (1987), 28(12), 1329-32  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 108:75063  
 GI



I



II



III

AB The title epi-pentenomycins (I; R = Me, Et, Me<sub>2</sub>CH) were prepared from 10-oxatricyclodecadienone (II; R<sub>1</sub> = OH, R<sub>2</sub> = H). Sulfonylmethylation of II with 4-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>Na and paraformaldehyde followed by alkylation gave sulfone II (R<sub>1</sub> = OEt, R<sub>2</sub> = 4-MeC<sub>6</sub>H<sub>4</sub>SO<sub>2</sub>CH<sub>2</sub>) which was **treated** with RONa (same R's) to give II (R<sub>1</sub> = OEt, R<sub>2</sub> = MeOCH<sub>2</sub>, EtOCH<sub>2</sub>, Me<sub>2</sub>CHOCH<sub>2</sub>). Regioselective reduction of the enol ethers with DIBAL gave enones II (R<sub>1</sub> = H) which were epoxidized with alkaline H<sub>2</sub>O<sub>2</sub> to give III. Flash vacuum thermolysis of III gave the corresponding cyclopentadienone epoxides which were converted into I by acidic hydrolysis and acetylation.

=> s alzheimer or dementia or cholestasis or neuropathy or stroke or multiple sclerosis or als

37548 ALZHEIMER

2900 ALZHEIMERS

37617 ALZHEIMER

(ALZHEIMER OR ALZHEIMERS)

11588 DEMENTIA

559 DEMENTIAS

11754 DEMENTIA

(DEMENTIA OR DEMENTIAS)

3913 CHOLESTASIS

10801 NEUROPATHY

1318 NEUROPATHIES

11294 NEUROPATHY

(NEUROPATHY OR NEUROPATHIES)

26986 STROKE

1952 STROKES

28193 STROKE

(STROKE OR STROKES)

373985 MULTIPLE

3212 MULTIPLES

376845 MULTIPLE

(MULTIPLE OR MULTIPLES)

22756 SCLEROSIS

27 SCLEROSES

22770 SCLEROSIS

(SCLEROSIS OR SCLEROSES)

13798 MULTIPLE SCLEROSIS

(MULTIPLE (W) SCLEROSIS)

4595 ALS

L18 96965 ALZHEIMER OR DEMENTIA OR CHOLESTASIS OR NEUROPATHY OR STROKE OR MULTIPLE SCLEROSIS OR ALS

=> d his

(FILE 'HOME' ENTERED AT 11:02:27 ON 23 DEC 2005)

FILE 'REGISTRY' ENTERED AT 11:02:37 ON 23 DEC 2005

L1 STRUCTURE UPLOADED  
L2 50 S L1  
L3 STRUCTURE UPLOADED  
L4 50 S L3

FILE 'STNGUIDE' ENTERED AT 11:06:12 ON 23 DEC 2005

FILE 'REGISTRY' ENTERED AT 11:06:17 ON 23 DEC 2005  
L5 72868 S L3 FULL  
L6 3420614 S 1/NR  
L7 19619 S L5 AND L6

FILE 'HCAPLUS' ENTERED AT 11:10:58 ON 23 DEC 2005

L8 33258 S L7  
L9 174454 S GROWTH FACTOR  
L10 421 S L9 AND L8  
L11 89 S L8 (S) L9

FILE 'REGISTRY' ENTERED AT 11:14:29 ON 23 DEC 2005

L12 STRUCTURE UPLOADED  
L13 0 S L12 FULL SUB=L5  
L14 1 S L12  
L15 69 S L12 FULL

FILE 'HCAPLUS' ENTERED AT 11:16:12 ON 23 DEC 2005

L16 44 S L15  
L17 14 S L16 AND (TREAT? OR THERAP?)  
L18 96965 S ALZHEIMER OR DEMENTIA OR CHOLESTASIS OR NEUROPATHY OR STROKE

=> s 116 and 118  
L19 1 L16 AND L18

=> d

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 2000:592544 HCAPLUS  
DN 133:176974  
TI Preparation of 4,5-dihydroxy-2-cyclopenten-1-one, 4-hydroxy-2-cyclopenten-1-one, and derivatives thereof as promoters for production of interleukin-12 and growth factor  
IN Ohnogi, Hiromu; Akiyama, Kaori; Tominaga, Takanari; Nishiyama, Eiji; Wu, Hua-kang; Tatsumi, Yoko; Sagawa, Hiroaki; Kato, Ikunoshin  
PA Takara Shuzo Co., Ltd., Japan  
SO PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000048586	A1	20000824	WO 2000-JP787	20000214
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP	1170007	A1	20020109	EP 2000-902942	20000214

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

PRAI JP 1999-42236 A 19990219  
JP 1999-108499 A 19990415  
JP 1999-264539 A 19990917  
WO 2000-JP787 W 20000214

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l16 and diabete  
29 DIABETE  
106220 DIABETES  
106223 DIABETE  
(DIABETE OR DIABETES)

L20 2 L16 AND DIABETE

=> d

L20 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 2000:592544 HCAPLUS  
DN 133:176974  
TI Preparation of 4,5-dihydroxy-2-cyclopenten-1-one, 4-hydroxy-2-cyclopenten-1-one, and derivatives thereof as promoters for production of interleukin-12 and growth factor  
IN Ohnogi, Hiromu; Akiyama, Kaori; Tominaga, Takanari; Nishiyama, Eiji; Wu, Hua-kang; Tatsumi, Yoko; Sagawa, Hiroaki; Kato, Ikunoshin  
PA Takara Shuzo Co., Ltd., Japan  
SO PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000048586	A1	20000824	WO 2000-JP787	20000214
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1170007	A1	20020109	EP 2000-902942	20000214
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	JP 1999-42236	A	19990219		
	JP 1999-108499	A	19990415		
	JP 1999-264539	A	19990917		
	WO 2000-JP787	W	20000214		

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 2

L20 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN  
AN 1999:34881 HCAPLUS  
DN 130:95322  
TI Preparation of 4,5-dihydroxy-2-cyclopenten-1-one derivatives as anticancer and apoptosis-inducing agents  
IN Kobayashi, Eiji; Koyama, Nobuto; Kato, Ikunoshin; Inami, Kaoru; Shiba,

Tetsuo  
 PA Takara Shuzo Co., Ltd., Japan  
 SO PCT Int. Appl., 38 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9900349	A1	19990107	WO 1998-JP2516	19980605
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2287282	AA	19990107	CA 1998-2287282	19980605
	AU 9875516	A1	19990119	AU 1998-75516	19980605
	AU 739505	B2	20011011		
	EP 1000923	A1	20000517	EP 1998-923158	19980605
	EP 1000923	B1	20031203		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1129569	B	20031203	CN 1998-806456	19980605
	AT 255554	E	20031215	AT 1998-923158	19980605
	ES 2209139	T3	20040616	ES 1998-923158	19980605
	JP 3639601	B2	20050420	JP 1999-505418	19980605
	TW 555744	B	20031001	TW 1998-87110072	19980623
	US 6111145	A	20000829	US 1999-419221	19991015
PRAI	JP 1997-187205	A	19970630		
	WO 1998-JP2516	W	19980605		
OS	MARPAT 130:95322				

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	74.70	471.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-10.22	-12.41

SESSION WILL BE HELD FOR 60 MINUTES  
 STN INTERNATIONAL SESSION SUSPENDED AT 11:24:42 ON 23 DEC 2005